Sudden cardiac death in CKD patients

Area of Science:

• Cardiology
• Nephrology
• Clinical Electrophysiology

Background:

• Chronic kidney disease (CKD) significantly elevates the risk of sudden cardiac death (SCD), with risk escalating as kidney function declines.
• Common causes of SCD in CKD patients include ventricular arrhythmias and bradyarrhythmia.
• Dialysis impacts the cardiovascular system through hemodynamic disturbances and electrolyte shifts, affecting myocardial electrophysiology.

Purpose of the Study:

• To investigate the multifaceted risks and management strategies for sudden cardiac death (SCD) in patients with chronic kidney disease undergoing dialysis.
• To evaluate the influence of dialysis on cardiovascular parameters and arrhythmia susceptibility.
• To highlight the limitations of current risk stratification and therapeutic interventions in this high-risk population.

Main Methods:

• Review of existing literature on SCD in CKD patients, focusing on dialysis-related effects and cardiovascular risk factors.
• Analysis of studies examining the impact of hemodialysis and peritoneal dialysis on hemodynamic stability and electrolyte balance.
• Evaluation of the efficacy of noninvasive tests and therapeutic interventions for SCD risk stratification and prevention in dialysis patients.

Main Results:

• End-stage renal disease itself appears to be a more significant driver of SCD than the specific type of dialysis (hemodialysis vs. peritoneal dialysis).
• Dialysis can exert both detrimental effects (e.g., worsening hypertension, left ventricular hypertrophy) and beneficial effects (e.g., fluid removal).
• Current noninvasive tests for SCD risk stratification in hemodialysis patients have limited positive predictive value, suggesting a need for combined approaches.

Conclusions:

• Individualized risk assessment is crucial for treatment decisions, including implantable cardioverter-defibrillator (ICD) implantation, in dialysis patients.
• Physicians should prioritize early identification, monitoring, and preventive measures for high-risk CKD patients due to the substantial hazard of cardiovascular mortality, including SCD.
• Further large-scale, placebo-controlled trials are needed to clarify the benefits of cardioprotective medications and ICDs in this population.